Bioprinting company Organovo has been consistently making headlines for their groundbreaking technology, which includes exVive 3D Human Liver Tissue and a soon-to-be-available 3D printed human kidney tissue. Today they announced that their wholly-owned subsidiary, Samsara Sciences Incorporated, has commenced commercial operations. Samsara will be Organovo's official cell provider, focusing on human liver cells such as hepatic stellate cells and hepatocytes. Read more at 3DPrint.com: http://3dprint.com/115090/organovo-samsara-sciences/